When does ivacaftor lose exclusivity in the EMA (EU) market?
Ivacaftor (Kalydeco) is covered by a mix of IP terms (basic patents) and regulatory exclusivities (EU regulatory data protection/exclusivity rules). The exact “loss of exclusivity” date in the European Medicines Agency (EMA) context depends on which legal barrier you mean:
- Patent expiry / patent landscape (varies by country and specific patent claims)
- Regulatory data exclusivity / market exclusivity (tied to marketing authorisation and EU rules)
You asked specifically about “loss of exclusivity ema,” but no jurisdiction (which EU member state) or which product version/strength you mean (e.g., Kalydeco ivacaftor for which age group/indication) is provided, and those details can change the date.
How do you check the actual EU “exclusivity expiry” date?
For EU market exclusivity questions tied to EMA authorization, the practical route is:
- Start from the EMA product information for the specific authorised ivacaftor product/indication.
- Then check whether barriers are patent-based (handled via national filings and litigation) or regulatory exclusivity (handled by EU regulatory framework and protection periods).
If you share the country (e.g., Germany/UK/France/Italy) and the exact product name/marketing authorisation (usually the brand is enough: Kalydeco, ivacaftor), I can narrow to the most relevant expiry concept and what typically governs it.
Are biosimilars or generics relevant for ivacaftor in the EU?
Ivacaftor is a small-molecule drug, so the typical “after exclusivity” competitive question is about generic entry rather than biosimilars. However, generic launch timing in the EU still depends on:
- whether any unexpired patents block it, even after regulatory exclusivity ends
- whether an application can be authorised based on regulatory data protection status
If exclusivity ends, what happens to prices and prescribing in the EU?
Once the relevant exclusivity/patent barriers clear, generics can enter, usually leading to:
- lower acquisition costs for payers
- more competitive pricing pressure
- potential formulary updates (timing varies by national health systems)
What’s the fastest way to get the exact date you need?
Reply with:
1) the brand/product (e.g., Kalydeco)
2) the EU country you care about (EMA is the EU-level regulator, but market entry is national)
3) whether you mean patent expiry or regulatory data/market exclusivity
…and I’ll structure the answer around the correct “loss of exclusivity” date for that definition.
Sources
No sources were provided in your prompt.